JO
ORKA

John Overdeck’s Oruka Therapeutics ORKA Stock Holding History

John Overdeck’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,364
Closed -$950K – 5516
2026
Q1 		$950K Sell
19,364
-9,202
-32% -$320K ﹤0.01% 3297
2025
Q4 		$866K Hold
28,566
– – ﹤0.01% 3031
2025
Q3 		$549K Sell
28,566
-3,776
-12% -$56K ﹤0.01% 2940
2025
Q2 		$363K Buy
32,342
+10,511
+48% +$110K ﹤0.01% 2721
2025
Q1 		$224K Buy
+21,831
New +$272K ﹤0.01% 2819

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

John Overdeck's ORKA Position: Q2 2026 in Review

John Overdeck sold out of Oruka Therapeutics (ORKA) in Q2 2026, closing a stake of 19,364 shares — an estimated $950K sold.

John Overdeck first reported a position in ORKA in Q1 2025 and held it in 5 quarters. The position peaked at $950K in Q1 2026. 254 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • John Overdeck reported no remaining Oruka Therapeutics position as of Q2 2026 after selling out during the quarter.
  • John Overdeck sold 19,364 Oruka Therapeutics shares in Q2 2026, an estimated $950K.
  • John Overdeck first reported a position in Oruka Therapeutics in Q1 2025 and held it in 5 quarters.
  • John Overdeck's Oruka Therapeutics position peaked at $950K in Q1 2026.
  • 254 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.